Pregnancy and the inflammatory bowel disease patient
Download
1 / 60

Pregnancy and the Inflammatory Bowel Disease Patient - PowerPoint PPT Presentation


  • 402 Views
  • Updated On :

Pregnancy and the Inflammatory Bowel Disease Patient. David G. Binion, M.D. Director, IBD Center Associate Professor of Medicine Medical College of Wisconsin Milwaukee, WI. Case 1: Pregnancy and IBD What we hope for ……….

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Pregnancy and the Inflammatory Bowel Disease Patient' - elina


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
Pregnancy and the inflammatory bowel disease patient l.jpg

Pregnancy and the Inflammatory Bowel Disease Patient

David G. Binion, M.D.

Director, IBD Center

Associate Professor of Medicine

Medical College of Wisconsin

Milwaukee, WI


Case 1 pregnancy and ibd what we hope for l.jpg
Case 1: Pregnancy and IBDWhat we hope for ………..

  • 31 year old female with history of UC well controlled on oral mesalamine for 5 years becomes pregnant with second child.

  • The patient states “I’ve never felt better than when I was pregnant.”

  • She continues IBD medications during pregnancy in combination with folic acid and prenatal vitamin and has vaginal delivery at term with healthy baby girl.

  • The patient breast feeds for 3 months and remains in remission.


Case 2 pregnancy and ibd what we hope to avoid l.jpg
Case 2: Pregnancy and IBDWhat we hope to avoid ………..

  • 30 year old female with 4 yr history of CD colitis controlled on azathioprine 150 mg daily and 10 mg/kg infliximab every 6 weeks becomes pregnant with second child.

  • The patient flares during first trimester. Prednisone 40 mg is started with gradual taper.

  • At 22 weeks she is hospitalized with BRBPR, increasing diarrhea and abdominal pain. Partial response to IV hydrocortisone, but unable to decrease. C. difficile negative.

  • IBD Surgery and high risk obstetric consults obtained. Both recommend medical treatment to control fulminant colitis if possible.

  • Next therapeutic option?


Introduction pregnancy and ibd l.jpg
Introduction: Pregnancy and IBD

  • Highest age adjusted incidence rates of IBD (15 – 30) overlap peak reproductive years.

  • Improved medical and surgical treatment of IBD has allowed patients with more significant illness to consider pregnancy and having children.

  • Optimal treatment algorithms for IBD patients during pregnancy have not been defined, including issues regarding high risk pregnancy.

  • Optimal management of reproductive heath in IBD patients is a challenge to gastroenterologists, obstetricians, IBD surgeons.


Goals pregnancy and ibd l.jpg
Goals: Pregnancy and IBD

  • Fertility – becoming pregnant.

  • Having an uneventful term pregnancy:

    • Avoiding preterm delivery

    • Avoiding severe flare r- isk for preterm delivery

  • Use of safe medications to maintain remission in mother during pregnancy.

  • Use of safe medications during post-partum and breast feeding to help mother maintain remission.


Overview l.jpg
Overview

  • Fertility/Fecundity Rates

  • Pregnancy Outcomes

  • Effects of Medications on Pregnancy

  • Special situations - IBD Surgery during pregnancy



Pregnancy and ileoanal pouch i l.jpg
Pregnancy and ileoanal pouch - I

  • 4 hospitals Sweden/Denmark

  • All women age 18-40 UC/IPAA 1992-8

  • Participation Rate:

    • 290/343 UC patients: 661/1200 controls

  • Fecundability rates

    • Before diagnosis: FR 1.46, p = 0.002

    • Before colectomy: FR 1.01 p = NS

    • After IPAA: FR 0.20, p<0.001

Olsen KO, et al. Gastroenterology 2002;122:15-19


Ipaa cumulative incidence of pregnancy within 5 years l.jpg
IPAA: Cumulative Incidence of PregnancyWithin 5 Years

1.0

0.8

Before diagnosis

Reference

0.6

Before surgery

Cumulative Incidenceof Pregnancy

After surgery

0.4

0.2

0.0

0

12

24

36

48

60

Time to Pregnancy (months)

Reprinted from Olsen KØ, et al. Gastroenterology. 2002;122:15-19 with permission from American Gastroenterological Association.


Female infertility after ipaa for uc l.jpg
Female Infertility After IPAA for UC

Infertility Rate(95% CI)

Success Rate in Becoming Pregnant (%)

Before surgery

Before diagnosis

After surgery

After diagnosis

P<.001

45

120

P<.0001

38.6%

(30.9-46.3)

40

97.5%

96.9%

95.8%

100

35

80

30

25

56.1%

60

20

13.3%

(4.7-21.9)

40

15

10

20

5

0

0

IPAA Patients

(N=153)

UC Patients Managed

Nonoperatively

(N=60)

IPAA Patients

(N=153)

UC Patients Managed

Nonoperatively

(N=60)

Johnson P, et al. Dis Colon Rectum. 2004;47:1119-1126.


Pregnancy and ileoanal pouch ii l.jpg
Pregnancy and ileoanal pouch - II

  • Effects of pelvic surgery – adhesions involving Fallopian tubes? “Tube factor”

    • Hudson (97): NE Scotland

      • Medical: 13% infertility, (7/15 resolved)

      • Surgical: 30% infertility, (7/16 resolved)

    • FAP patients with IPAA also with decreased fecundability (54%), but normal after IRA [Olsen 2003]

    • Perforated appendicitis does not lead to reduced rates of fecundability

  • Important consideration for patients counseled for IPAA in UC. Rationale for biologic therapy in UC.



Summary female fertility l.jpg
Summary: Female Fertility

  • Ulcerative Colitis

    • Similar to the general population prior to colectomy

    • Significantly decreased after IPAA

  • Crohn’s Disease

    • Studies vary

    • Infertility partly voluntary

      • (dyspareunia, illness, MD advise)

    • Surgery: decreased fertility



Ibd pregnancy complications and outcomes mcw 1998 2004 l.jpg
IBD pregnancy complications and outcomes MCW 1998 - 2004

  • Pregnancies in 37 of 416 women (CD 316;UC 110)

  • 51 total pregnancies reviewed (CD 81%;UC 19%)

  • Mean pregnancy age 28 y/o

  • Obstetric and IBD related complications in 57% of pregnancies

  • 6 pregnancies required hospitalization (12%)

  • Spontaneous abortion in 11.8% (mean age 30.6 years

  • Term pregnancy in 70% CD and 80% UC (all children reported healthy)

Beaulieau DB, et al. Gastroenterology 128: A316, 2005.


Slide16 l.jpg

MCW IBD Center’s Pregnancies

Pregnancies in pts with

Crohn's Disease 81%

Pregnancies in pts with

UlcerativeColitis 19%

51 pregnancies reviewed in 37 women

Beaulieau DB, et al. Gastroenterology 128: A316, 2005.


Timing of ibd flares during pregnancy l.jpg
Timing of IBD flares during pregnancy

Numbers of IBD pregnancies

7

6

5

4

CD

UC

3

IBD

2

1

0

1st

2nd

3rd

pp

Pregnancy trimester

Beaulieau DB, et al. Gastroenterology 128: A316, 2005.


Slide18 l.jpg

IBD Flares during pregnancy

Disease flare in 19% of CD pregnancies

Disease flare in 30% of UC pregnancies

  • IBD flare occurred in 21.2% of the IBD pregnancies

  • IBD flare occurred most commonly during the first trimester (63.6% of flares)

  • IBD maintenance therapy had been discontinued in 43% of patients experiencing first trimester flare.


Slide19 l.jpg

IBD post-partum flares

13.7% of IBD patients

post-partum flare

  • 57% of post partum flares occurred within the 1st month of delivery

  • Post-partum flare was associated with drug cessation in 28.6% of patients


Slide20 l.jpg

IBD obstetric complications

  • Spontaneous abortions in 11.8% of IBD patients

  • Pre-eclampsia in 7.8% of IBD patients

  • Gestational diabetes in 2% of IBD patients


Effect of ibd on birth outcomes sweden 1991 92 l.jpg
Effect of IBD on Birth Outcomes -Sweden, 1991-92

IBD No IBD Adjusted OR

n=756 n>239,000 (95% CI)

Late fetal death 0.5% 0.3% 1.3 (0.6-2.6)

Infant death 0.5% 0.5%

LBW 1.2% 0.6% 2.2 (1.1-4.2)

Very LBW 4.5% 2.9% 1.6 (1.1-2.2)

Very Preterm 1.9% 1.0% 1.8 (1.1-3.1)

Preterm 6.3% 4.3% 1.5 (1.1-2.0)

SGA 4.0% 2.9% 1.4 (0.97-2.0)

C-section 15% 10% 1.5 (1.2-1.8)

Kornfeld et al, Am J Obstet Gynecol 1997;177:942-6.


Birth outcomes in ibd state of washington 1987 96 l.jpg
Birth Outcomes in IBD-State of Washington, 1987-96

CUC CD Controls OR, CUC OR, CD

n=107 n=155 n=1308 (95% CI) (95% CI)

LBW 7.6% 16.8% 5.3% 1.1 (0.4-3.3) 3.6 (2.2-5.9)

Preterm 10.4% 15.2% 7.2% 1.0 (0.4-2.5) 2.3 (1.4-3.8)

SGA 10.5% 15.2% 5.3% 1.7 (0.8-3.8) 2.3 (1.3-3.9)

Congenital abnl 7.9% 3.4% 1.7% 3.8 (1.5-9.8) 2.0 (0.8-5.5)

C-section 28.7% 28.4% 20.2% 1.3 (0.8-2.2) 1.6 (1.1-2.3)

Dominitz et al, Am J Gastroenterol 2002;97:641-8.


Slide23 l.jpg

Outcomes: Ulcerative Colitis

  • Hungarian Case Control Surveillance of congenital anomalies (CA): 1980-1996

  • UC: 71 cases (0.3%): 95 controls (0.2%)

  • OR: 1.3 (95% CI=0.9-1.8) [Adjusted for parity, age, SAS/other drugs]

    • Limb deficiencies: OR=6.2 (2.9-13.1)

    • Obstructive urinary CA: OR=3.3 (1.1-9.5)

    • Multiple CA: OR=2.6 (1.3-5.4)

Norgard et al, Am J Gastroenterol 2003;98:2006-10.


Slide24 l.jpg

Outcomes: Crohn’s Disease

  • Fonager (1998): Danish pop. based study

    • 510 births vs. 3018 controls, 1982-92

    • Increased risk of LBW

      • OR = 2.4 (95% CI 1.6-3.7)

    • Increased risk of preterm birth

      • OR = 1.6 (95% CI 1.1-2.3)


Pregnancy outcomes population based studies l.jpg
Pregnancy Outcomes:Population Based Studies

  • Kornfeld: Am J Obstet Gynecol 1997 (n=756 IBD)

  • Fonager: Am J Gastroenterol 1998 (n=510 CD)

  • Norgard: Am J Gastroenterol 2000 (n=1531 UC)

  • Dominitz: Am J Gastroenterol 2002 (n=107 UC, 155 CD)


Slide26 l.jpg

Predictors of Poor Outcome

  • Active Disease (UC and CD)

    • 50% vs 21% (p<0.05) abnormal outcomes

    • Activity at conception => Fetal loss

    • Activity during pregnancy => LBW

    • Independent of medication use

  • Ileal Crohn’s Disease (p = 0.035) Moser

    • Not consistently found in other studies

  • Previous bowel resection (p = 0.065) Moser


Effect of pregnancy on uc disease activity at conception l.jpg

n=528

n=227

66%

45%

34%

27%

24%

NoRelapse

Relapse

WorsenedActivity

Continued

Activity

DecreasedActivity

Inactive

Active

Effect of Pregnancy on UC: Disease Activity at Conception

Miller JP. J R Soc Med. 1986;79:221-5.


Effect of pregnancy on cd disease activity at conception l.jpg

73%

n=186

n=93

34%

33%

32%

27%

NoRelapse

Relapse

WorsenedActivity

Continued

Activity

DecreasedActivity

Inactive

Active

Effect of Pregnancy on CD: Disease Activity at Conception

Miller JP. J R Soc Med. 1986;79:221-5.


Slide29 l.jpg

Pregnancy outcomes in women with inflammatory bowel disease: population based cohort studyU Mahdevan, WJ Sandborn, S Azmi, S Kane, DK Li,D Corley

  • Cohort study among members of the Northern California Kaiser Permanente population

  • Identified 493 pregnant women with a pre-birth diagnosis of IBD and frequency matched 493 non-pregnant women for age and hospital of pregnancy

  • Univariate analyses included chi-square and t-test; multivariate analyses used unconditional logistic regression. All analyses were two tailed.


Patient characteristics l.jpg
Patient Characteristics population based cohort study

  • N=324 non-IBD vs 305 IBD (preliminary)

  • Mean Age at Conception: 30.1 vs 30.8

  • Smokers 61 (19%) vs 51 (17%) [p = 0.46]

  • 203 UC and 96 CD

    • IBD Duration: 6.1 years

    • Immunosuppressant Use: 12 (4%)

    • Aminosalicylate Use: 142 (47%)

    • Corticosteroid Use: 57 (19%)


Ibd pregnancy outcomes l.jpg
IBD Pregnancy Outcomes population based cohort study


Summary ibd pregnancy outcomes l.jpg
Summary population based cohort studyIBD Pregnancy Outcomes

  • Preliminary Analysis

  • IBD pts are more likely to have an adverse pregnancy outcome and complicated labor than women without IBD

  • Adverse neonatal outcome not increased in IBD

  • Impact of immunosuppressant medications is limited by a small sample size in available data


Medical therapy in conception and pregnancy l.jpg
Medical Therapy in Conception and Pregnancy population based cohort study


Drugs in pregnancy l.jpg
Drugs in Pregnancy population based cohort study

  • Limited data - Pharmaceutical trials almost never performed in pregnant women.

  • PDRâ medicolegal disclaimer: use in pregnancy is not recommended unless benefits justify risk to the fetus.

  • Half of all pregnancies are unplanned.

  • FDA classification (A, B, C, D, X)

    • Ambiguous

    • Difficult to interpret and use in counseling

Koren G et al. N Engl J Med. 1998;338:1128.


Fda teratogenicity classification for drugs during pregnancy l.jpg
FDA Teratogenicity Classification for Drugs during Pregnancy population based cohort study

  • Category A: Controlled studies show no risk

    • No IBD medications in Category A

  • Category B: No evidence of risk in humans

  • Category C:

    • Animal reproduction studies show adverse effect

    • No adequate studies in humans

    • Drug’s benefits in pregnant women may be acceptable despite its potential risk

  • Category D: Positive Evidence of Risk

  • Category X: Contraindicated in Pregnancy


Nutritional therapy l.jpg
Nutritional Therapy population based cohort study

  • Elemental Diet

    • Case reports of effectiveness in acute flares during pregnancy [Teahon, Gut 1991]

    • Important to maintain nutrition to the fetus

  • Total Parenteral Nutrition

    • Less desirable, but case reports of effectiveness [Gatenby, Human Nutrition 1987]


Fish oil l.jpg
Fish Oil population based cohort study

  • Essential Fatty acids (EFA) and Docosahexaenoic acid (DHA)

    • Potential antithrombotic effect

    • Prolong gestation

    • No evidence of prevention of proteinuric pregnancy

  • Mild benefit in Crohn’s disease

  • Concern regarding risk of metal toxicity – USDA recommendation 8/03 to limit fish consumption during pregnancy


Pharmaceutical therapy aminosalicylates i l.jpg
Pharmaceutical Therapy population based cohort studyAminosalicylates - I

  • Aminosalicylates – Category B

    • Only controlled trial (Diav-Citrin 1998 Gastroenterology)

      • 165 pts. Prospectively followed, controls with smoking/Etoh NOT IBD: Mean daily dose 2 gm

      • No teratogenicity

      • Maternal weight gain significantly lower on 5ASA

      • preterm delivery, LBW

    • Ludvigson (2002) LBW if mother treated with mesalamine or steroids during pregnancy


Pharmaceutical therapy aminosalicylates ii l.jpg
Pharmaceutical Therapy population based cohort studyAminosalicylates - II

  • Sulfasalazine should be given with folic acid 1 mg BID

    • Folic acid: neural tube defects, CV, urinary tract, cleft palate

    • Case reports of congenital malformation

  • Placental and Breast Milk Transfer Occurs

    • Potential of allergic reaction in newborn with watery diarrhea

    • SAS not associated with kernicterus or displacement of bilirubin form albumin


Corticosteroids l.jpg
Corticosteroids population based cohort study

  • No evidence of teratogenicity in humans

    • Poorer outcomes likely due to worse disease

  • Theoretical concern of adrenal suppression in newborn

    • Cross placenta

    • 10-12% of maternal concentration

  • Safe in breast feeding


Antibiotics l.jpg
Antibiotics population based cohort study

  • Metronidazol/Ciprofloxacin

    • Low risk of teratogenicity

      • Metronidazole: case-control study and meta-analysis

      • Ciprofloxacin: prospective controlled study

    • Growing cartilage may be a target for cipro toxicity’

    • Breast feeding is not advised

    • Minimal benefit in Crohn’s and UC

    • No data on long-term safety


Azathioprine 6 mp l.jpg
Azathioprine/6-MP population based cohort study

  • Purine analogues

  • Interfere with synthesis of adenine and guanine ribonucleosides, precursors of DNA and RNA

  • Act predominantly on rapidly dividing cells

  • Incorporation of TGN nucleotides into cellular nucleic acids (cytotoxicity)

  • Controversy - Class D label for pregnancy but commonly used in IBD, RA and transplant


Teratogenicity of 6mp aza l.jpg
Teratogenicity of 6MP/AZA population based cohort study

  • Teratogenic in animals (mice, rabbits, rats)

    • Given IV/IP at supratherapeutic doses (low oral bioavailability: 47% AZA, 16% 6MP)

    • Increased cleft palate, ocular, skeletal, urogenital anomalies, hydrocephalus

    • Poor oral bioavailability may produce levels too low to have substantial teratogenic effect

  • No consistent increase in human teratogenicity

  • Fetal liver in early pregnancy lacks inosinate pyrophosphorylase to convert AZA to active metabolites

    • Polifka and Friedman (Teratology 65:240-261. 2002)


Human studies 6mp aza l.jpg
Human Studies: 6MP/AZA population based cohort study

  • Transplantation Experience

    • Frequency of congenital anomalies in renal tx 0.0-11.8% in 27 clinical series

    • No recurrent pattern of anomalies seen

    • No increase in anomalies in NTPR (Armenti 1994) in kidney transplant recipients on AZA

    • Immunosuppression is never stopped in setting of organ tranplant

  • No congenital anomalies in rheumatic disease, SLE


Norgard aliment pharm ther 2003 l.jpg
Norgard (Aliment Pharm Ther 2003) population based cohort study

  • Population based prescription registry, Denmark

    • 9 pregnancies (30d before concept/1st trimester)

    • 10 pregnancies (exposed entire pregnancy)

    • Outcomes vs (1) 19,418 pregnancies no drugs (2) any drug (3) 6MP/AZA >3 mos before pregnancy

  • 11 pts: 55% IBD, 45% other disease

    • Congenital malform OR = 6.7 (95%CI 1.4-32.4)

    • Mortality OR = 20 (2.5-161.4)

    • Preterm Birth OR = 6.6 (1.7-25.9)

    • LBW OR = 3.8 (0.4-33.3)

  • After exclusion of most ill pt (AIH), no statistical significance in OR


Aza 6 mp l.jpg
AZA/6-MP population based cohort study

  • Experience in IBD

    • Alstead (1990): 14 pts: 7 entire pregnancy

      • No congenital anomalies

    • Khan (2000): 8 preg/6 pt no complications

    • Francella (2003): Retrospective

      • 79F (24 UC), 76M (27 UC), 325 pregnancies

      • No diff. b/w 6MP, no 6MP

    • Breastfeeding not recommended


Outcomes of 6mp aza exposure l.jpg
Outcomes of 6MP/AZA exposure population based cohort study

Francella A, et al. Gastroenterology 2003;124:9


Cyclosporine l.jpg
Cyclosporine population based cohort study

  • Teratogenicity

    • Not in animals, probably not in humans

    • One case in humans, administered at 29 weeks.

    • Healthy fetus at 34 weeks

    • Used in fulminant colitis, better than emergent colectomy

  • Breast feeding not advised

  • Reserved for fulminant disease vs colectomy


Infliximab and pregnancy category b l.jpg
Infliximab and pregnancy (Category B) population based cohort study

  • Katz JA et al. (Am Journal Gastroenterol 2004)

  • Infliximab Safety Database

    • 146 identified pregnancies

    • 82 CD, 1 UC, 10 RA, 3 unknown

  • Outcome 96 pregnancies, n = 100 births

    • Live birth 64 (67%)

      • 1 preterm 24 wks (died), 1 tetrology Fallot, 1 sepsis survived, 1 intestinal malrotation in twin

    • Miscarriage 14(15%) (1 stillbirth on MTX)

    • Therapeutic termination 18 (19%) (pts. choice)

  • Data similar to expected for UC/CD note exposed to INF


Infliximab in pregnancy outcomes of women exposed to infliximab during pregnancy l.jpg
Infliximab in Pregnancy: population based cohort studyOutcomes of Women Exposed to Infliximab During Pregnancy

80

67

67

67

70

66

60

Live births

50

Miscarriages

Proportion of Patients (%)

40

Therapeutictermination

30

20

19

17

17

20

16

15

13

11

10

0

General population

Crohn’s disease

All infliximab patients(N=96)

Infliximab patients with CD (N=82)

Katz JA, et al. Am J Gastroenterol. 2004;99:2385-2392.

Ventura et al. National Center for Health Statistics Vital Health Stat 2000;21:1-59Hudson et al. Int J Gynaecol Obstet 1997;58:229-237.


Intentional infliximab in pregnancy l.jpg
Intentional Infliximab in Pregnancy population based cohort study

10 Crohn’s disease patients intentionally exposed to infliximab during pregnancy

8 women receivedmaintenance infusions

2 women receivedinitial infusions

10 Live Births

Congenitalmalformations

(N=0)

IUGR

(N=0)

SGA

(N=0)

Preterm

(N=3)

LBW

(N=1)

  • 8 Caesarean sections: 2 active luminal, 3 perianal disease, 1 preterm

Mahadevan U, et al. Aliment Pharmacol Ther. 2005;21:733-738.


High serum infliximab levels in newborn of a mother treated during pregnancy l.jpg
High serum infliximab levels in newborn population based cohort studyof a mother treated during pregnancy

Breast fed 7 wks

Breast feed resumed Wk 11

–2

0

2

4

6

10

13

Time (weeks) from birth

Infliximab + + + + + infusions (10 mg/kg)

+

Birth 41 wks

Immune studies at 6 months:

T and B lymphocytes normal

IgG, IgM and IgA levels normal

Vasiliauskas E et al. DDW 2005, #148


Heparin and ibd pregnancy l.jpg
Heparin and IBD pregnancy population based cohort study

  • 20% of IBD patients have hypercoagulability risk

  • Increased risk of hypercoagulability during pregnancy

  • Heparin and low molecular weight heparin have established track record in maternal-fetal medicine

  • Potential adjunctive role in IBD

  • Case report – heparin rescue therapy in hospitalized, refractory CD colitis

  • Low mol wt heparin used as colitis rescue tx in Case 2 (60 mg subcutaneous injection b.i.d.)

DN Prajapati et al. Inflamm Bowel Dis. 2002; 8:192-5.


Parenteral iron therapy l.jpg
Parenteral iron therapy population based cohort study

  • Oral iron may be poorly tolerated, abdominal pain

  • Patients with obstructive symptoms may not tolerate prenatal vitamin. Consider for gastroduodenal CD.

  • Hyperemesis gravidarum – poor oral tolerance

  • Intravenous iron sucrose 100 mg dosage

  • FDA class B


Contraindicated medications l.jpg
Contraindicated Medications population based cohort study

  • Methotrexate

    • Known abortifacient

    • Teratogenic (skeletal defects, cleft palate)

    • 3 month “washout” in females and males prior to planned pregnancy

  • Thalidomide

    • 20-30% Rate of Birth defects or fetal death

    • limb malformation (phocomelia)


Special consideration l.jpg
Special Consideration population based cohort study

  • Perianal Crohn’s Disease

  • Fulminant Ulcerative Colitis

  • Patients with IPAA


Perianal crohn s disease l.jpg
Perianal Crohn’s Disease population based cohort study

  • Active perianal disease: Caesarean section recommended

    • No history (1/39) or inactive (0/11) perianal disease at birth, risk of relapse very low post-vaginal delivery

    • 4/4 with active perianal disease worsened post-vaginal delivery [Ilnycky 1999 AJG Manitoba database]

  • Episiotomy may predispose to perineal disease (17.9%) without prior history of disease


Fulminant ulcerative colitis l.jpg
Fulminant Ulcerative Colitis population based cohort study

  • 2005 – look for C. Difficile infection

  • Nutrition

  • Intravenous corticosteroids

    • 75% successful

  • Infliximab

  • Heparin compounds

  • Cyclosporine

    • 1 case report. IV CSA 10 days, 34th wk delivery

  • Colectomy

    • 50-60% fetal mortality reported

    • Rare to have fulminant colitis in pregnancy

    • Surgery in 2nd trimester is preferable

    • Tocolytic therapy – high risk obstetrics in OR


Pouch function and pregnancy l.jpg
Pouch Function and Pregnancy population based cohort study

  • Reversible deterioration of pouch function during pregnancy

  • No long-term detriment to pouch function

  • Mode of delivery determined by obstetric indications

  • Ravid Dis Col Rec 2002


Summary ibd and pregnancy l.jpg
Summary: IBD and pregnancy population based cohort study

  • Fertility

    • IPAA Surgery clearly reduces fertility rates in women

    • Role of medications in fertility unclear

  • Pregnancy Outcomes

    • Complicated pregnancies occur in majority of patients

    • Increased rates Preterm birth, SGA LBW

    • No increase in congenital anomalies

    • Aggressive management of IBD flare during pregnancy with medications is warranted

  • Medications

    • Yes: 5ASA, Steroids, 6MP/AZA, Infliximab

    • No: MTX, Thalidomide


ad